SynthesisBulletin of the World Health Organization2012
Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis.
Synthesis in Bulletin of the World Health Organization, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis.European journal of epidemiology · 2015Pooled it
- Pooled it
- Immunopharmacological design of a multi-epitope vaccine targeting hepatitis C virus genotype 3a.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Immuno-Informatics Analysis of Pakistan-Based HCV Subtype-3a for Chimeric Polypeptide Vaccine Design.Vaccines · 2021Article
- Mortality trend due to Hepatitis B and C in the city of São Paulo, 2002-2016.Revista de saude publica · 2020Article
- Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey.Harm reduction journal · 2019Article
- Prevalence of hepatitis C among HIV-1, HIV-2 and dually reactive patients: A multi-country cross-sectional survey in West Africa.Journal of public health in Africa · 2018Article
- Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes.World journal of gastroenterology · 2016Review
- Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.PloS one · 2016Article
- Cytokine Response Associated with Hepatitis C Virus Clearance in HIV Coinfected Patients Initiating Peg Interferon-α Based Therapy.Mediterranean journal of hematology and infectious diseases · 2016Article
- Hepatitis C genotype 4: The past, present, and future.World journal of hepatology · 2015Review
- Challenges in managing HIV in people who use drugs.Current opinion in infectious diseases · 2015Review
- Global distribution and prevalence of hepatitis C virus genotypes.Hepatology (Baltimore, Md.) · 2015Article
- Antiviral treatment of hepatitis C.BMJ (Clinical research ed.) · 2014Review
- HCV transmission in industrialized countries and resource-constrained areas.Nature reviews. Gastroenterology & hepatology · 2014Review
- Article
- Prevalence and epidemiological correlates and treatment outcome of HCV infection in an Italian prison setting.BMC public health · 2013Article
- Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges.Future virology · 2013Article
- Income and patient-reported outcomes (PROs) after primary total knee arthroplasty.BMC medicine · 2013Article
- Rapid virological&End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the effectiveness of treatment for hepatitis C virus (HCV) infection in low- and middle-income countries and identify factors associated with successful outcomes.
methodsWe performed a systematic review and meta-analysis of studies of HCV treatment programmes in low- and middle-income countries. The primary outcome was a sustained virological response (SVR). Factors associated with treatment outcomes were identified by random-effects meta-regression analysis.
findingsThe analysis involved data on 12 213 patients included in 93 studies from 17 countries. The overall SVR rate was 52% (95% confidence interval, CI: 48-56). For studies in which patients were predominantly infected with genotype 1 or 4 HCV, the pooled SVR rate was 49% (95% CI: 43-55). This was significantly lower than the rate of 59% (95% CI: 54-64) found in studies in which patients were predominantly infected with other genotypes (P = 0.012). Factors associated with successful outcomes included treatment with pegylated interferon and ribavirin, infection with an HCV genotype other than genotype 1 or 4 and the absence of liver damage or human immunodeficiency virus infection at baseline. No significant difference in the SVR rate was observed between weight-adjusted and fixed-dose ribavirin treatment. Overall, 17% (95% CI: 13-23) of adverse events resulted in treatment interruption or dose modification, but only 4% (95% CI: 3-5) resulted in treatment discontinuation.
conclusionThe outcomes of treatment for HCV infection in low- and middle-income countries were similar to those reported in high-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.